Replimune
Replimune
REPL
NASDAQ
10.17
USD
-15.32%
About
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.
RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response.
It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 561.1K |
| Three Month Average Volume | 23.2M |
| High Low | |
| Fifty-Two Week High | 20.83 USD |
| Fifty-Two Week Low | 4.92 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 29 May 2024 |
| Price and Volume | |
| Current Price | 10.17 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -4.69% |
| Thirteen Week Relative Price Change | 80.31% |
| Twenty-Six Week Relative Price Change | 3.11% |
| Fifty-Two Week Relative Price Change | -60.25% |
| Year-to-Date Relative Price Change | 1.88% |
| Price Change | |
| One Day Price Change | -8.05% |
| Thirteen Week Price Change | 92.98% |
| Twenty-Six Week Price Change | 13.38% |
| Five Day Price Change | 0.30% |
| Fifty-Two Week Price Change | -50.20% |
| Year-to-Date Price Change | 20.64% |
| Month-to-Date Price Change | 1.70% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 6.09798 USD |
| Book Value Per Share (Most Recent Quarter) | 6.24288 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 6.09798 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 6.24288 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.43767 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.24162 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.27198 USD |
| Normalized (Last Fiscal Year) | -3.24162 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.24162 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.27198 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.24162 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -3.27198 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 6.84958 USD |
| Cash Per Share (Most Recent Quarter) | 6.86758 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.16458 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -3.19266 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.86779 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 6.97% |
| Tangible Book Value (5 Year) | 22.13% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 16.84% |
| Total Debt (5 Year) | 60.98% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -4.09% |
| EPS Change (Trailing Twelve Months) | -10.33% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -397,938,000 |
| Net Debt (Last Fiscal Year) | -349,731,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 18 |
| Long Term Debt to Equity (Most Recent Quarter) | 16 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 11 |
| Current Ratio (Most Recent Quarter) | 13 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -191,129,000 |
| Free Cash Flow (Trailing Twelve Months) | -192,928,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 19 |
| Total Debt to Equity (Most Recent Quarter) | 17 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -38.05% |
| Return on Assets (Trailing Twelve Months) | -38.64% |
| Return on Assets (5 Year) | -29.08% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -46.42% |
| Return on Equity (Trailing Twelve Months) | -46.79% |
| Return on Equity (5 Year) | -33.68% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -40.71% |
| Return on Investment (Trailing Twelve Months) | -41.09% |
| Return on Investment (5 Year) | -30.56% |